Buyout vote looming, Celgene files for ozanimod OK (again), with a multibillion-dollar bet riding on every step
It took more than a year, but Celgene has managed to re-file its application for ozanimod a few days ahead of the end of Q1, as it said it would.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
